Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
21 Feb 24
8-K
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
18 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
11 Oct 23
DEF 14A
Definitive proxy
25 Sep 23
PRE 14A
Preliminary proxy
15 Sep 23
424B5
Prospectus supplement for primary offering
12 Sep 23
EFFECT
Notice of effectiveness
11 Sep 23
CORRESP
Correspondence with SEC
6 Sep 23
D
$42.57 mm in equity, sold $42.57 mm, 48 investors
18 Aug 23
S-3
Shelf registration
18 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
7 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
15 May 23
424B5
Prospectus supplement for primary offering
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Regulation FD Disclosure
17 Apr 23
S-8
Registration of securities for employees
14 Mar 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Ikena Oncology Appoints Owen Hughes as Board Chair
19 Dec 22
8-K
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
28 Nov 22
8-K
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
10 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
10-Q
2022 Q1
Quarterly report
12 May 22
EFFECT
Notice of effectiveness
6 May 22
CORRESP
Correspondence with SEC
3 May 22
UPLOAD
Letter from SEC
2 May 22
Latest ownership filings
SC 13G/A
FMR LLC
11 Mar 24
4
Caroline Germa
5 Mar 24
3
Caroline Germa
5 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Omega Fund VI, L.P.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Jeffrey Ecsedy
2 Feb 24
4
Jotin Marango
2 Feb 24
4
Mark Manfredi
2 Feb 24
SC 13G
GILEAD SCIENCES, INC.
19 Oct 23
4/A
David P Bonita
21 Sep 23
4/A
Change in insider ownership (amended)
21 Sep 23
SC 13D/A
ORBIMED ADVISORS LLC
21 Sep 23
4
Change in insider ownership
14 Sep 23
4
David P Bonita
14 Sep 23
SC 13D/A
ORBIMED ADVISORS LLC
14 Sep 23
4
Iain D. Dukes
13 Jun 23
4
Owen Hughes
13 Jun 23
4
Otello Stampacchia
13 Jun 23
4
Maria Koehler
13 Jun 23
4
David P Bonita
13 Jun 23
4
Richard Wooster
13 Jun 23
4
JEAN FRANCOIS FORMELA
13 Jun 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
FMR LLC
10 Jan 23
4
Sergio L. Santillana
5 Jan 23
4
Jeffrey Ecsedy
5 Jan 23
4
Xiaoyan Michelle Zhang
5 Jan 23
4
Mark Manfredi
5 Jan 23
4
Jotin Marango
5 Jan 23
4
Owen Hughes
19 Dec 22
3
Owen Hughes
19 Dec 22
SC 13G/A
FMR LLC
11 Oct 22
4
Change in insider ownership
24 Jun 22
4
David P Bonita
24 Jun 22
4
Otello Stampacchia
13 Jun 22
4
Iain D. Dukes
13 Jun 22
4
Ronald C Renaud JR
13 Jun 22